Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Usana Health Sciences (USNA) Revenue (2016 - 2026)

Usana Health Sciences has reported Revenue over the past 17 years, most recently at $250.2 million for Q2 2026.

  • Quarterly Revenue changed 0.27% to $250.2 million in Q2 2026 from the year-ago period, while the trailing twelve-month figure was $925.9 million through Apr 2026, up 5.67% year-over-year, with the annual reading at $925.3 million for FY2026, 8.28% up from the prior year.
  • Revenue was $250.2 million for Q2 2026 at Usana Health Sciences, up from $226.2 million in the prior quarter.
  • Over five years, Revenue peaked at $362.3 million in Q1 2022 and troughed at $200.2 million in Q3 2024.
  • The 5-year median for Revenue is $230.6 million (2022), against an average of $239.6 million.
  • Year-over-year, Revenue plummeted 37.09% in 2022 and then rose 10.79% in 2025.
  • A 5-year view of Revenue shows it stood at $228.0 million in 2022, then dropped by 3.02% to $221.1 million in 2023, then decreased by 3.38% to $213.6 million in 2024, then grew by 0.03% to $213.7 million in 2025, then increased by 17.1% to $250.2 million in 2026.
  • Per Business Quant, the three most recent readings for USNA's Revenue are $250.2 million (Q2 2026), $226.2 million (Q1 2026), and $213.7 million (Q3 2025).